MSC-NTF Cell Immunomodulation: Effects on T and B Regulatory Cells (790)
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: We evaluated the immunomodulatory properties of MSC-NTF cells and their effects on T and B regulatory cells.
Background: MSC-NTF cells (NurOwn®) are autologous, differentiated bone-marrow derived mesenchymal stem cells (MSC) that secrete neurotrophic factors (NTFs), regulatory miRNAs that demonstrate neuroprotection and immunomodulation in preclinical models and are currently under evaluation in phase 2 progressive MS and phase 3 ALS trials. Disordered T and B regulatory cell function has been implicated in the pathogenesis of ALS and MS. Furthermore, IL-10 production by regulatory B cells, may ‘regulate the regulators’, and has been viewed as a protective mechanism in ALS and MS animal models, possibly through effects on microglial networks.
Design/Methods: MSC-NTF cells were generated from healthy controls and were co-cultured with human peripheral blood mononuclear Cells (PBMC) or isolated B cells. The effect of MSC-NTF cells on proliferation of T or B cells and on induction of regulatory T or B cells was evaluated using flow cytometry. ELISA was used to measure secretion of different cytokines and IgM.
Results: MSC-NTF cells inhibited IFN-g and TNF-a secretion and CD4+/ CD8+ T cell proliferation when co-cultured with activated PBMCs, and induced CD4+CD25+FoxP3+ regulatory T cells. MSC-NTF cells did not affect B cells proliferation, however we observed that they induced CD24hiCD38hi regulatory B cells, stimulated IL-10 secretion, and inhibited B cell IgM secretion.
Conclusions: Neuroinflammation is a prominent pathological feature of ALS and progressive MS. Reduced T and B regulatory function may contribute to disease progression, and lower IL-10 levels may be associated with reduced ALS function and with higher disability and MRI lesion load in secondary progressive MS. The immunomodulatory properties of MSC-NTF cells, including their effects on T and B regulatory cells, combined with neuroprotective and repair mechanisms may extend the potential therapeutic benefits of MSC-NTF cells.
Disclosure: Dr. Aricha has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Abramov has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Semo has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Kaspi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Lebovits has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics. Dr. Lebovits has received compensation for serving on the Board of Directors of BrainStorm Cell Therapeutics. Dr. Kern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with BrainStorm Cell Therapeutics Ltd. BrainStorm Cell Therapeutics Ltd. employee
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
- No related articles found.